Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medco, Caremark To Sponsor Medicare Cards Despite Concern With Rx Plans

Executive Summary

Pharmacy benefit managers appear to be embracing the Medicare-endorsed drug discount card program but are remaining wary of offering stand-alone Medicare Rx plans

You may also be interested in...



Medco Adds 15-20 Specialty Pharmacy Products Under Accredo Deal

Medco's 10-year agreement with Accredo Health will increase its specialty pharmacy offering by 15 to 20 products

Medco Adds 15-20 Specialty Pharmacy Products Under Accredo Deal

Medco's 10-year agreement with Accredo Health will increase its specialty pharmacy offering by 15 to 20 products

Caremark Reports Single-Digit Rx Spending Growth In 2003, Medco 10.5%

Caremark held its prescription drug cost growth to the single digits in 2003, President A.D. Frazier reported during the company's year-end conference call Feb. 3

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel